

Ca-PRI 2018 - Keynote speakers



Professor Roger Jones

Roger Jones has been the Editor of the British Journal of General Practice since 2010. Previously he was Professor and Head of General Practice at King's College, London, and a general practitioner in an inner city practice in Lambeth, South East London.

Roger was educated at Oxford and trained in medicine at St Thomas's Hospital, London. After hospital jobs in internal medicine he became a GP in a market town in Hampshire, where he set up an open-access endoscopy service, which led to a life-long interest in primary care gastroenterology, including the early diagnosis of gastrointestinal cancer. He was a senior lecturer in general practice in Southampton and held the foundation chair in Primary Health Care at the University of Newcastle upon Tyne. He is the founding President of the Primary Care Society for Gastroenterology in the UK, and of the European Society of Primary Care Gastroenterology, and was Editor-in-Chief of the Oxford Textbook of Primary Medical Care.



Dr. Kevin Oeffinger

Dr. Oeffinger is a family physician, the founding Director of the Duke Center for Onco-Primary Care, and the Director of the Supportive Care and Survivorship Center at Duke Cancer Institute. He is a Professor in the Department of Medicine at Duke University Medical Center. Dr. Oeffinger has a long-standing record of NIH-supported research in cancer screening and survivorship and has served in a leadership capacity in various cancer-focused and primary care-focused national committees and organizations, including the American Society of Clinical Oncology, the American Cancer Society, and the American Academy of Family Physicians.



Professor Jes Søgaard

Jes Søgaard is Chief Economist at the Danish Cancer Society, professor of Health Economics at University of Southern Denmark, Health Faculty, Institute of Clinical Medicine, and an Adjunct Professor at Aarhus University.

He represents the Danish Cancer Society in the Access to Medicine Initiative under European Cancer Leagues and is a co-founder of the newly established Nordic Research Network on Standardized Cancer Pathways. For 14 years, 1998 through 2012, Jes Søgaard was the CEO of the Danish Health Services Research Institute and before that he taught and conducted health services research at universities in Denmark and Sweden.



Dr. Stephen Taplin, MD, MPH

Dr. Stephen Taplin is the Deputy Associate Director of the Healthcare Delivery Research Program within the National Cancer Institute's Division of Cancer Control and Population Sciences. He is an expert in the field of cancer screening and built his research career around the problems that arose from his clinical experience as a primary care physician. Before joining NCI he was responsible for delivery and evaluation of a breast cancer-screening program serving 100,000 women in an integrated health plan. He joined the National Cancer Institute as a Senior Scientist in 2003 after being a Professor in the Department of Family Medicine at the University of Washington and an Investigator in the Center for Health Studies at Group Health in Seattle. He has led the development of research into how individuals, groups and organizations act and interact to affect cancer care delivery. He publishes regularly in peer-reviewed journals including work on mammography and the conceptualization of problems and interventions in cancer care delivery. His current work emphasizes understanding how teams affect healthcare delivery.



Sara Hiom, Director Of Early Diagnosis & Health Professional Engagement, Cancer Research UK

Sara trained and worked in biomedical research at University College London and then at the Medical Research Council's National Institute for Medical Research (NIMR) before joining Cancer Research UK in 2000. Since then she has built expertise, developed and led teams within the charity in prevention, screening, early diagnosis, evaluation and analysis, and primary care support. Now with responsibility for Cancer Research UK's early diagnosis strategy, to help achieve our ambition of more people surviving cancer for longer, Sara's department is focusing on the crucial role that health professionals, especially in primary care, play in the diagnostic process. This includes CRUK's 'Facilitator Programme', trained experts who work to support primary care in evidence-based approaches to improving diagnosis, screening and prevention.

Sara has led Cancer Research UK's involvement in early diagnosis initiatives in the NHS, including key innovations such as the ACE Programme (Accelerate, Coordinate, Evaluate) trialling 'Multidisciplinary Diagnostic Centres' as well as the International Cancer Benchmarking Partnership (ICBP) and the Marmot Review of breast cancer screening. She is a Trustee of the British Thoracic Oncology Group and takes every opportunity to champion early diagnosis research and evaluation.



Professor Elsken van der Wall

Elsken van der Wall (1960) has studied medicine at the University of Utrecht and subsequently specialized in internal medicine at the University Medical Center of Utrecht (UMCU). In the Dutch Cancer Institute / Het Antoni van Leeuwenhoekhuis in Amsterdam she further specialized in medical oncology while performing research that resulted in her PhD degree on 'high-dose chemotherapy in solid tumors' in 1995. From 1995 till 2003 she held a position as medical oncologist at the department of medical oncology at the VU Medical Center in Amsterdam. During this time she spend 14 months as a basic scientist at the Sidney Kimmel Cancer Institute at Johns Hopkins Medical Institutions (JHMI) in Baltimore, USA . She

subsequently became part-time associate professor at JHMI which position she still holds. In 2003 she was appointed full professor of medicine at the UMCU and in 2005 she was additionally appointed as distinguished professor of Utrecht University. She is head of the Research Program Cancer of the UMCU. Her out-patient clinical activities focus entirely on patients with breast cancer. Together with prof. dr. Paul van Diest, head of the Department of Pathology, she supervises the laboratory for breast cancer research at the UMC Utrecht. The focus of her scientific research is on breast carcinogenesis and she is co-author of close to 200 peer-reviewed scientific papers. In 2010 she was knighted by former HRM Queen Beatrix of the Netherlands, for her contribution to increase breast cancer awareness.



HW Nijman, MD PhD

HW Nijman, MD PhD, is head of the Department of Obstetrics & Gynecology at the University Medical Center Groningen. His research line focuses on investigating tumor immunological principles as well as preclinical/translational development of novel anti-cancer immunotherapeutics. In 2002, he was awarded a personal grant by the Dutch Cancer Society with the aim of building his own translational research group at the UMCG. Since then, he has run a number of (pre-) clinical studies on the prognostic role, and therapeutic exploitation of the immune system in gynecological malignancies. Hans Nijman has a proven track-record in translational research and therapeutic cancer vaccination trials.

Optimal cancer therapy, requires expert care delivered in specialized treatment centers. As a cancer clinician, Hans Nijman is therefore spear-heading a nationwide initiative focused on regional network formation in cancer patient care (Citrien-project - towards regional cancer networks).



Professor Jon Emery

Prof Jon Emery is the Herman Professor of Primary Care Cancer Research at the University of Melbourne and the Primary Care Research and Education Lead at the Victorian Comprehensive Cancer Centre. He is an NHMRC Practitioner Fellow, Director of the Cancer Australia Primary

Care Collaborative Cancer Clinical Trials Group (PC4), and a Visiting Research Fellow at the Department of Public Health and Primary Care, University of Cambridge. He was previously Head of the School of Primary, Aboriginal and Rural Health Care at the University of Western Australia.

He studied medicine at Cambridge and Oxford and obtained his DPhil at Oxford on computer decision support to assess cancer risk in general practice. His research program applies principles of implementation science and focuses on the role of primary care across the cancer continuum including prevention, early diagnosis and survivorship, aiming to improve the integration of health services. He leads a collaborative program of cancer research between Melbourne and Cambridge with Dr Fiona Walter on cancer screening, risk assessment and early diagnosis. He has published over 190 papers and has been a Chief Investigator on research grants and awards totalling over \$AUD17 million and GBP16 million. He sits on several national and international advisory committees related to cancer screening and diagnosis, and cancer research.



Professor Dr. Niek J de Wit

Niek de Wit is professor in Primary Care and head of department at the Julius Center of Health Sciences and Primary Care of the University Medical Center in Utrecht, the Netherlands (www.juliuscenter.nl). He is medical director of the Julius health centers, the academic primary care practice in Leidsche Rijn (www.lrjg.nl).

His initial research focussed on the management of gastro-intestinal symptoms in primary care. In the past 10 years he has been working at the interface of clinical primary care practice and academic research, and initiated innovative programs on cardiovascular disease, elderly care, and cancer. His cancer research involved early diagnosis, shared decision making and follow-up care from general practice.

He has been participating in the guideline development program of the Dutch College of General Practice, and co-authored the Future strategy 2022 of the College. In 2012 he was appointed in the Quality of care Board of the Dutch Ministry of Health.



Wanda de Kanter

Wanda de Kanter is a Dutch pulmonologist since 1990. She started working at VU University Medical Center in Amsterdam and the Red Cross Hospital in Beverwijk as a general chest physician, mainly treating smoking related pulmonary diseases (lung cancer, COPD, pneumothorax, etc).

For 5 years now, she is working as an oncologist in the Netherlands Cancer Institute (NKI-Antoni van Leeuwenhoek) in Amsterdam, treating patients with lung cancer. She is a member of the Advisory Board of the National Lung Cancer Patients Society (Longkanker Nederland) and also a member of the IASLC Prevention and Tobacco team. In 2009 she was awarded with the prestigious Muntendam Prize by the Dutch Cancer Society. The 50.000-euro prize money was spent on the documentary *Burning Desire* portraying the stigma felt by nine patients with smoking related lung cancer.

In 2008, together with colleague pulmonologist and friend Pauline Dekker she published the best seller *The Netherlands stops! Smoking* (60.000 copies sold) and two years later she was the co-author of the handbook for health care workers on *Motivational Interviewing (Motiveren kun je leren)*. She also is the co-founder of the biggest cessation clinic in the Netherlands.

In 2009 she co-founded the Youth Smoking Prevention Foundation (Stichting Rookpreventie Jeugd, SRPJ), which she also chairs, aimed at making smoking history by preventing children from starting. In 2013 SRPJ initiated the website *TabakNee (TobaccoNo)* that with the help of investigating journalists exposes the tobacco lobby in the Netherlands. The foundation's activities led to hundreds of articles in newspapers and magazines, items on national television and lectures.

In 2013 SRPJ filed charges against the State of the Netherlands for violation of WHO FCTC Art. 5.3. SRPJ did not win this case in court, but the Dutch Deputy Minister of Health did send out a protocol to all government officials and politicians, both national and local, on how to behave in relation to contacts with representatives of the tobacco industry. Since then tobacco industry people complain about the closed doors they meet in government.

In 2016, Anne Marie van Veen, a 42-year-old lung cancer patient, a mother of four, asked Wanda if it would be possible to file criminal charges against the tobacco industry. SRPJ took up this request and with the help of one of the country's best criminal lawyers a criminal complaint against four tobacco companies active in the Netherlands was filed in September 2016. The case was supported by a grass roots movement, *Sick of Smoking*, which got support from more than 25,000 people.

Later The Dutch Cancer Society, the Dutch Journal of Medicine (NTvG), the association of physiotherapists Claudicationet, the Federation of Cancer Patients, the Netherlands Cancer Institute, several academic hospitals and ten organizations active in addiction care joined the complaint.

More details can be found on:

<http://stichtingrookpreventiejeugd.nl/over-rookpreventie-jeugd/english>

<https://sickofsmoking.nl/en/>